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The precise role of the transcription factor nu-
clear factor kappa B (NF-k kB) in the regulation of
cell survival and cell death is still unresolved and
may depend on cell type and position in the cell
cycle. The aim of this study was to determine if
three pharmacologic inhibitors of NF-k kB, pyrroli-
dine dithiocarbamate, N-tosyl-L-lysl chloromethyl
ketone and calpain I inhibitor, induce apoptosis
in a murine macrophage cell line (RAW 264.7) at
doses similar to those required for NF-k kB inhibi-
tion. We found that each of the three inhibitors
resulted in a dose- and time-dependent increase
in morphologic indices of apoptosis in unstimu-
lated, LPS-stimulated and TNF-stimulated cells.
Lethal doses were consistent with those required
for NF-k kB inhibition. We conclude that nuclear
NF-k kB activation may represent an important
survival mechanism in macrophages.
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Introduction
Nuclear factor kappa B (NF-kB) is a complex of
dimeric transcription factors (p50, p65, c-rel,
Rel B) activated by tumor necrosis factor (TNF),
reactive oxygen species, phorbol myristate acet-
ate (PMA), lipopolysaccharide (LPS), as well as
serine/threonine and tyrosine kinases. NF-kB
plays a signi￿cant role in immunity and in￿am-
mation; genes regulated by NF-kB include inter-
leukins 1, 2, 6 and 8, inducible nitric oxide
synthase, the major histocompatibility complex
Class I, the adhesion molecules, ICAM, VCAM
and ELAM, and the immunoglobulin k light
chain (for a review see reference 1). In addition,
there is now data to suggest that NF-kB may
also play a role in the regulation of cell survival,
cell death and oncogenesis:2 for example, in-
hibition of p65, a transcriptionally active sub-
unit of NF-kB, with antisense messenger RNA
has been shown to inhibit tumorigenicity of
transformed cell lines and tumor growth in
animals;3 Bcl-3, a molecule related to I-kB and
which is unable to inhibit nuclear binding of
the p65 subunit, has been linked to the
development of B-cell lymphomas.4
The precise role of NF-kB in the regulation of
cell death is still a matter of controversy. Ini-
tially, several lines of evidence appeared to
indicate a role for the excessive activation of
NF-kB as a cause of apoptosis: nuclear binding
of transcriptionally active NF-kB p50/p65 het-
erodimers was noted to follow initiation of
apoptosis in a variety of cell lines,5- 8 and three
distinct pharmacologic inhibitors of NF-kB, pyr-
rolidine dithiocarbamate (PDTC), N-tosyl-L-lysyl
chloromethylketone (TPCK) and N-acetyl cys-
teine, were shown to inhibit apoptosis in HL-60
cells, human thymocytes, prostate carcinoma
and neuroblastoma cell lines.9,10 In some of
these experiments, however, the doses of these
agents required to inhibit apoptosis were lower
than those required to inhibit NF-kB, suggesting
that their protective effects were not necessarily
due to their ability to inhibit NF-kB.11 The
ability of the TNF-receptor both to activate NF-
kB and to execute an apoptosis program were
initially suspected to be causally related, futher
supporting a pro-apoptotic function for NF-kB.
Recent studies, however, have demonstrated
that the initiation of apoptosis and the activa-
tion of NF-kB by TNF are separate, and possibly,
mutually exclusive events. 12- 14
In spite of the fact that various compounds
which share the ability to inhibit NF-kB includ-
ing PDTC, N-acetyl cysteine, genistein, dexa-
methasone and staurosporine can cause
apoptosis at doses similar to those required for
NF-kB inhibition,15- 21 inhibition of NF-kB itself
had not been proposed as a mechanism of
apoptosis until very recently. The ￿rst evidence
in favor of a pro-survival role for NF-kB came
from a study of mice with a homozygous
deletion of the gene for the p65 component of
NF-kB who underwent early embryonic death
characterized by apoptosis of liver cells.22 A
second piece of evidence came from the ￿nding
of an NF-kBbinding site on the promoter region
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apoptosis. 23 Finally, three separate reports were
published recently which demonstrated preven-
tion of TNF-mediated apoptosis by induction of
NF-kB in vitro. 24- 26 In a fourth study, the NF-kB
inhibitor, TPCK was found to induce apoptosis
in unstimulated WEHI B-cell lymphoma cells.27
Although this evidence supports a pro-survi-
val role for NF-kB, other recent studies have
demonstrated that the precise relationship be-
tween NF-kB and cell death is still unresolved.
Grilli et al. for example, have reported that
aspirin and sodium salicylate protect against
glutamate-induced apoptosis by inhibiting NF-
kB in preparations of primary neurons.28 Simi-
larly, Tsai et al. have shown that PDTC protects
neurons from cell death at the same doses at
which it causes apoptosis in smooth muscle
cells. 15 These con￿icting results point to the
need for further studies to de￿ne the conditions
and cell types in which NF-kB inhibitors either
cause or inhibit apoptosis. The answers to these
questions are of particular importance because
NF-kB inhibitors have been proposed as poten-
tial therapeutic agents for in￿ammatory dis-
ease29 and cancer.25
The aim of the current study was to deter-
mine if three pharmacologically distinct inhibi-
tors of NF-kB (PDTC, TPCK, and Calpain I
inhibitor) induce apoptosis in a transformed
murine macrophage cell line at doses required
for the inhibition of NF-kB. We also sought to
determine if activation of the cells with either




RAW 264.7 cells, from a transformed murine
peritoneal macrophage cell line, were obtained
from ATCC (Rockville, MD); recombinant mur-
ine TNF-a was purchased from R&D Systems
(Minneapolis, MN); [c-32P]ATP and Hyper￿lm
were obtained from Amersham Life Sciences
(Arlington Heights, IL); calpain I inhibitor was
purchased from ICN (Costa Mesa, CA); Cellular
DNA Flow Cytometric Analysis Kit was obtained
from Boehringer Mannheim (Indianapolis, IN);
polynucleotide kinase and kinase buffer for
electrophoretic mobility shift assays were ob-
tained from Promega (Madison, WI); NF-kB
consensus oligonucleotide was obtained from
Stratagene (La Jolla, CA); fetal calf serum was
purchased from HyClone (Logan, UT). All other
reagents were purchased from Sigma (St. Louis,
MO).
Cell culture
RAW 264.7 cells were cultured in Dulbecco’s
modi￿ed Eagle’s medium with 10% fetal calf
serum containing , 0.6 E.U. lipopolysaccharide
(LPS), penicillin (100 units/ml) streptomycin
(100 mg/ml) and NaHCO3 (2·2 g/l). Cells were
exposed for 18 h to varying doses of each
inhibitor as follows: PDTC, 0, 25, 50, 100 mM;
TPCK, 0, 10, 25, 50 mM; and calpain I inhibitor,
0, 5, 10, 25 mM. In addiitonal experiments, cells
were exposed for 6, 12, 18 or 24 h to either
100 mM PDTC, 50 mM TPCK, 10 mM calpain I
inhibitor or vehicle (control). Some cells were
concomitantly exposed to 10 nM phorbol myr-
istate acetate (PMA), 3 ng/ml TNF , 1 mg/ml LPS
or 10 mg/ml of cycloheximide (CHX). Cells
were then rinsed in phosphate buffered saline
(PBS) or Tris buffered saline (TBS), scraped and
pelleted in preparation for cell death analysis or
nuclear extracts, respectively.
Electrophoretic mobility shift assay
Nuclear extracts were prepared as previously
described.30 After determining the protein con-
tent of nuclear assays using a standard assay
(Bio-RAD, Hercules, CA), 2 mg of each sample
was incubated for 15 min with 5 ml of binding
buffer (5 3 TBE; 25%glycerol), 1 ml poly dI:dC
(0·25 mg/ml) and 1 ml 50 mM dithiothreitol.
Samples were then incubated for 30 min with a
32P-labeled consensus NF-kB binding oligonu-
cleotide. To ensure speci￿city of binding, nega-
tive control samples were coincubated with
unlabeled oligonucleotide (‘cold competitor’).
One ml of gel 103 loading buffer (250 mMTris-
HCl, pH 7.5, 0.2% bromophenol blue, 40%
glycerol) was added to each sample and sam-
ples were loaded on a 9% polyacrylamide
nondenaturing gel and run at 190 Vfor 3±4 h in
0.25 3 TBE. Gels were exposed to X-ray ￿lm at
- 708 Covernight.
Cell death assays
Cell death by apoptosis was quanti￿ed by one
of two methods. Cells from all treatment groups
were resuspended in PBS containing 5 mg/ml of
acridine orange and examined under a ￿uores-
cent microscope for morphologic changes con-
sistent with apoptosis (nuclear condensation
and fragmentation, membrane blebbing). The
presence of apoptosis was con￿rmed by per-
forming the TUNEL end-labeling assay which
measures double-stranded DNA breaks by ￿ow
cytometry.31 Brie￿y, cells were washed twice in
cold PBS/1%BSA and then ￿xed with 100 ml of
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were centrifuged at 188 3 g, washed twice with
PBS/1% BSA, and resuspended in 100 ml of
permeabilization solution (0.1%Triton X-100 in
0.1% sodium citrate) for 2 min on ice. After
washing twice, cells were resuspended in 50 ml
of TUNEL reaction mixture (terminal deoxynu-
cleotidyl transferase and nucleotide mixture)
and incubated for 60 min at 378 C in a dark,
humidi￿ed chamber. After washing samples
twice in PBS, cells were resuspended in 250±
500 ml of PBS and analyzed by ￿ow cytometry.
Cells undergoing apoptosis were expressed as a
percentage of total cells.
Statistical analysis
Comparisons among treatment groups were
made by ANOVA and the Tukey±Kramer Multi-
ple Comparisons Test using Instat (GreaftPad
Software, San Diego, CA) software.
Results
Induction of apoptosis by NF-kB
inhibitors
Apoptosis was assessed at 18 h for each inhibi-
tor. Treatment with each of the three inhibitors
resulted in an increase in the percentage of cells
undergoing apoptosis as assessed by acridine
orange (Fig. 1) and TUNEL staining (Fig. 2).
Compared to no treatment, PDTC, TPCK, and
calpain I inhibitor each caused signi￿cant, dose-
dependent increases in apoptosis as assessed by
acridine orange staining (Fig. 1). Calpain I
inhibitor was the most effective of the three
agents at killing cells with an EC50 of between 5
and 10 mM. PDTC was the least effective of the
three agents with an EC50 of approximately
100 mM. The EC50 for TPCK was approximately
40 mM(Fig. 1). Apoptosis induction by each of
the inhibitors at 18 h was con￿rmed using ￿ow
cytometry and the TUNELassay (Fig. 2).
Time course of apoptosis
The mean percentage of cells undergoing apop-
tosis as assessed by acridine orange staining at
6, 12, 18 and 24 h for each inhibitor was
calculated (Fig. 3). Maximal induction of apop-
tosis by TPCK (50 mM) and PDTC (100 mM)
occurred at 18 h. Calpain I inhibitor (10 mM)
induced maximal killing at 12 h. Apoptosis
became detectable at about 6 h post-treatment
and began to decrease by 24 h post-treatment
for all inhibitors. There was little morphologic
evidence of apoptosis prior to 6 h for any of the
inhibitors tested (data not shown).
Effect of PMA
Experiments were conducted to determine if
induction of apoptosis by NF-kB inhibitors
could be overcome by concurrent signals which
normally induce NF-kB. Neither TNF nor LPS
afforded signi￿cant protection against cell death
caused by any of the three inhibitors (data not
shown). PMA (10 nM) led to a reduction in the




























FIG. 1. Dose-response curves for apoptosis caused by NF-
kB inhibitors. RAW 264.7 cells were incubated for 18 h with
doses of PDTC (Ð Ð Ð ), TPCK (-----) and calpain I inhibitor
(.....) in the range 0±100mM. Dosage data is plotted on a
log scale. Percentage of apoptotic cells was quanti® ed by
counting the number of cells with morphologic character-
istics of apoptosis per 100 cells using acridine orange
staining. Calpain I inhibitor (25 mM), TPCK (50 mM) and PDTC
(100 mM) all caused highly signi® cant (P , 0·001) increases
in apoptosis compared to controls. Error bars represent
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FIG. 2. Effects of NF-kB inhibitors on apoptosis measured
by TUNEL/¯ ow cytometry. RAW 264.7 cells were incubated
for 18 h with either no treatment, 100 mM PDTC, 50 mM
TPCK, or 10 mM calpain I inhibitor. The percentage of cells
undergoing apoptosis was quanti® ed by ¯ ow cytometry
using TUNEL staining and is depicted on the ordinate. ,
signi® cant increases in apoptosis compared to controls
(P , 0·05). Error bars represents SEM. Each experiment was
repeated at least three times.
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NF-kB inhibitors and apoptosis(100 mM), TPCK (50mM) and calpain I inhibitor
(10 mM) (Fig. 4). Only in the case of calpain I
inhibitor, however, was this reduction signi￿-
cant (P, 0·001).
Effect of cycloheximidine
Cycloheximide has been reported to both pre-
vent and induce apoptosis, presumably depend-
ing on whether it inhibits transcription of death
genes or of survival genes.32,33 In our experi-
ments, cycloheximidine (10 mg/ml) offered no
protection against apoptosis caused by PDTC
(100 mM), TPCK (50 mM) and calpain I inhibitor
(10 mM) at 18 h (Fig. 5). By itself, however,
cycloheximide also induced extensive apoptosis
at 18 h. These results suggest that cyclohexi-
mide may be blocking induction of a pro-
survival gene in an additive fashion with NF-kB
inhibitors.
Effects of inhibitors on NF-kB binding
by EMSA
T o determine if apoptosis occurred at the same
doses as NF-kB inhibition by PDTC, TPCK and
calpain I inhibitor, electrophoretic mobility shift
assays were performed using nuclear extracts
from cells incubated for 18 h with different
doses of each of the three inhibitors (Fig. 6).
PDTC, at doses of 50 mMand higher, effectively
inhibited the upper band of the two-band NF-kB
characteristically seen on EMSA gels. The upper
band corresponds to p50±p65 heterodimers.
The lower band, which was not inhibited by
PDTC, corresponds to p50±p50 homodimers,
considered to be transcriptionally inactive. At
doses above 10 mM, TPCK inhibited the bands
corresponding to both the p50±p65 heterodi-
mer and the p50±p50 homodimer. Interestingly,
in some experiments, there was formation of a
new band of higher molecular weight than the
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FIG. 3. Apoptosis caused by NF-kB inhibitors as a function
of time. RAW 264.7 cells were incubated for 6, 12, 18 and
24 h with no treatment (d ), 100 mM PDTC (s ), 50 mM TPCK
(j ) or 10 mM calpain 1 inhibitor (m ). The percentage of cells
undergoing apoptosis was assessed by acridine orange
staining and is shown on the ordinate. Error bars represent
SEM. Each experiment was repeated at least three times.
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FIG. 4. Effects of PMA on apoptosis induced by NF-kB
inhibitors. RAW 264.7 cells were incubated for 18 h with
either PMA (10 nM), PDTC (100 mM), TPCK (50 mM), calpain I
inhibitor (10 mM) or PMA with PDTC, TPCK with PMA or
calpain I inhibitor with PMA. The mean percentage of cells
undergoing apoptosis as assessed by acridine orange
staining is represented on the abscissa. Error bars represent
SEM. , signi® cant reduction in apoptosis in cells treated
with a combination of calpain I inhibitor and PMA com-
pared to cells treated with calpain I inhibitor alone
(P , 0·05). Each experiment was repeated at least three
times.
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FIG. 5. Effects of cycloheximide (CHX) on apoptosis in-
duced by NF-kB inhibitors. RAW 264.7 cells were incubated
for 18 h with CHX (10 mg/ml), calpain I inhibitor (10 mM),
TPCK (25 mM) or PDTC (100 mM). The percentage of cells
undergoing apoptosis as assessed by acridine orange
staining is shown on the abscissa. Error bars represent
SEM. , signi® cant increase in apoptosis (P , 0·001) in
treated cells compared to control cells; §, signi® cant in-
crease (P , 0·001) in apoptosis in cells treated with TPCK
and CHX compared to cells treated with TPCK alone; +
signi® cant increase (P, 0·01) in apoptosis in cells treated
with both PDTC and CHX compared to cells treated with
PDTC alone. Each experiment was repeated at least three
times.
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tor inhibited NF-kB (both p50±p50 and p50±
p65 dimers) binding at doses of 1 mM and
higher. As with TPCK, an unidenti￿ed higher
molecular weight band appeared at doses of
10 mMcalpain I inhibitor and higher.
These results show that the EC50 for the
induction of apoptosis by all three inhibitors
was slightly higher than the minimum dose
required for NF-kB inhibition, indicating that
NF-kB inhibition and apoptosis occur within the
same dose range. Calpain I inhibitor was the
most effective inhibitor of NF-kB, and PDTC
was the least effective, re￿ecting the order of
ef￿cacy of these compounds in inducing apop-
tosis. Inhibition of NF-kB (maximal at 2 h)
occurred prior to morphologic evidence of
apoptosis (maximal at 18 h). This suggests that
an event downstream of NF-kB inhibition (such
as inhibition of gene transcription) would be
required to provide a causal link between the
two events.
Discussion
We have shown that three pharmacologically
distinct inhibitors of NF-kB ± PDTC, TPCK and
calpain I inhibitor ± each causes apoptosis of
RAW 264.7 murine macrophages in a dose-
dependent fashion. Further, doses of these
inhibitors which cause apoptosis are similar to
those which inhibit NF-kB binding as detected
by electrophoretic mobility shift assay. Simul-
taneous activation of the cells with either LPS
or TNF fails to reverse apoptosis. Simultaneous
treatment with PMA partially reverses apoptosis
but the effect is only signi￿cant in calpain I
inhibitor-treated cells.
The ability of TPCK, calpain I inhibitor and
PDTC to cause apotosis has been previously
documented in other cells lines,14,34- 37 but an
association with inhibition of NF-kB had not
been made until very recently when four simul-
taneous reports were published demonstrating
a direct association between NF-kB inhibition
and apoptosis. 24- 27 Three reports (based on
studies conducted in ￿broblasts, macrophages,
Jurkat T cells, human bladder cancer cells and
human ￿brosarcoma cells) showed that NF-kB
activation suppresses TNF-a-induced apoptosis
and that NF-kB inhibition (either by transfection
with a dominant-negative I-kB alpha or by
‘knock-out’ of RelA), augments TNF-induced
apoptosis. 24- 26 Our study con￿rms these results
in macrophages and extends them to unstimu-
lated, and LPS-stimulated, cells. In a fourth
study, inhibition of NF-kB by TPCK induced
apoptosis in WEHI 121 B-cell lymphoma cells
even in the absence of TNF-stimulation.27 Inter-
estingly, as in the case of RAW cells, WEHI cells
have constitutive NF-kBactivation.
TPCK and calpain I inhibitor are both pro-
tease inhibitors. TPCK is an inhibitor of serine
chymotrypsin-like proteases and has been
shown to inhibit both the phosphorylation and
proteolytic degradation of I-kB.38 Calpain I
inhibitor is an inhibitor of neutral cysteine
proteases and is known to prevent I-kB proteo-
lytic degradation.39 There is some evidence to
suggest that calpain itself may be involved in
the regulation of I-kB degradation.40 However, it
is also possible that the apoptosis-inducing
effects of these two inhibitors could derive from
their ability to inhibit the 26S proteasome, a
multifraction protease which degrades and re-
cycles a variety of intracelullar proteins. Indeed,
the ability of PMA partially to reverse apoptosis
induced by calpain I inhibitor may be related to
its ability to activate the proteasome, most likely
downstream from the effects of calpain I
inhibitor. The proteasome’s role in NF-kB activa-
tion is to degrade phosphorylated, ubiquitin-
conjugated, cytoplasmic I-kB, therby releasing
NF-kB dimers for nuclear binding.41 The protea-
some is also involved in the degradation of
other proteins which are critical for cell cycle
regulation including cyclins, p53 and protein
kinase C.42- 44 Thus, it is not possible to
determine from our data whether the effects
of the two protease inhibitors tested here are
due to the inhibition of NF-kB per se, or to
inhibition of the degradation of another protein
such as p5336 involved in cell cycle regulation.
However, in light of the recently published
reports directly linking NF-kB inhibition to
apoptosis by gene transfection, 24- 26 it is likely
FIG. 6. Electrophoretic mobility shift assay ± Effects of NF-
kB inhibitors on NF-kB binding. RAW 264.7 cells were
incubated for 2 h with either no treatment (lane 1); PDTC,
25 mM (lane 2); PDTC, 50 mM (lane 3); PDTC, 100 mM (lane 4);
TPCK, 5 mM (lane 6); TPCK, 10 mM (lane 7); TPCK, 25mM (lane
8); TPCK, 50 mM (lane 9); calpain I inhibitor, 1 mM (lane 10);
calpain I inhibitor, 5 mM (lane 11); calpain I inhibitor, 10 mM
(lane 12); calpain I inhibitor, 25 mM (lane 13). Bands
corresponding to p50±p65 heterodimers and to p50±p50
homodimers are indicated by arrows. The uppermost band
seen in lanes 7, 9 and 12 is unidenti® ed. This experiment
was repeated at least three times.
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NF-kB inhibitors and apoptosisthat the effects of TPCK and calpain I inhibitor
on apoptosis may be directly related to their
ability to inhibit NF-kB transloction to the
nucleus.
In some cell types, both TPCK and calpain I
inhibitor have been shown to be effective
inhibitors rather than inducers of apop-
tosis.11,45- 49 Their dual effects on apoptosis may
derive from their ability to inhibit proteases
involved in the characteristic nucleosomal clea-
vage of apoptosis independently of their ability
to inhibit NF-kB.45,46,49 Alternatively, it is possi-
ble that both underactivation and overactivation
of NF-kB may each cause apoptosis, giving NF-
kB inhibition a dual role in apoptosis. It is well
known, for example, that both excessive cellu-
lar activation (‘activation-induced’ cell death)
and insuf￿cient cellular stimulation (growth-
factor withdrawal) can each lead to cell death,
most likely by different mechanisms. Finally, the
divergent effects of these protease inhibitors on
apoptosis may be dependent both on cell type
and position in the cell cycle. The possibility
exists, for example, that cycling cells are
susceptible to apoptosis by these agents
whereas terminally differentiated cells arrested
in G0/G1 are not.
The mechanism by which PDTC inhibits NF-
kB binding is still unclear. However, it has been
suggested that its inhibitory effects of NF-kB are
due to its metal-binding and/or antioxidant
properties.50,51 Oxidants may activate NF-kB
through a mechanism independent of the pro-
teasome. An oxidant-sensitive tyrosine kinase
had recently been shown to release I-kB from
NF-kB without associated I-kB degradation.52 It
is unlikely that PDTC’s actions are similar to
those of either TPCK or calpain I inhibitor. In
unstimulated RAW cells, TPCK and calpain I
inhibitor inhibited both bands of the NF-kB
complex, presumably corresponding to p50±
p65 and p50±p50 dimers. However, in our
hands, PDTC only inhibited the higher molecu-
lar weight band corresponding to the p50±p65
dimer. In addition, administration of TPCK and
calpain I inhibitor results in the appearance of a
new unidenti￿ed band on EMSA of higher
molecular weight than the p50±p65 hetero-
dimer. The fact that PDTC only inhibits p50±
p65 dimers but still induces apoptosis, supports
the hypothesis, raised by ￿ndings in the p65
kock-out mouse,21 that p65 but not p50 is
critical for cell survival.
It is interesting that PDTC was substantially
less effective than TPCKor calpain I inhibitor in
inducing apoptosis in our cell line. One reason
may be that higher doses of PDTC are required
to inhibit NF-kB. In addition, anti-oxidants such
as PDTC may be less potent inducers of
apoptosis than protease inhibitors by virtue of
their ability to scavenge free radicals. Finally,
PDTC (but not, to our knowledge, TPCK or
calpain I inhibitor) has the ability to induce
metallothionein (unpublished work), a metal-
regulatory protein which itself inhibits apop-
tosis. 53
Our ￿ndings regarding PDTC’s ability to
induce apoptosis are consistent with the re-
cently reported results of Tsai et al. who found
that PDTC, at doses of 25±150 mM, induced
apoptosis in rat and human aortic smooth
muscle cells.15 These authors concluded that
PDTC’s ability to induce apoptosis might be
related to its antioxidant properties because
similar results were obtained with N-acetyl
cysteine. When serum-deprived PC12 cells were
used in the same study, however, PDTC was
protective at doses of 100 mM. It is clear from
these divergent results that the actions of PDTC,
like TPCK and calpain I inhibitor, are dependent
on the cell type and cell cycle conditions.
PDTC’s ability to induce death in smooth
muscle cells and macrophages, two cell types
which proliferate on conditions of chronic
in￿ammation, (while sparing nerve cells and
possibly other terminally differentiated cells)
suggests that PDTC and other NF-kB inhibitors
might be useful anti-in￿ammatory agents.
Although the three compounds tested in this
study inhibited NF-kB within 2 h, there was a
time delay of 6 h before the appearance of
apoptosis. This suggests that they are regulating
gene transcription and protein translation of
downstream effectors of cell survival or death.
W e used cycloheximide to test the hypothesis
that the three compounds might be inducing
the transcription of a programed cell death
gene, since cycloheximide has been reported to
block apoptosis caused by other agents.33 Cyclo-
heximide not only failed to block apoptosis
caused by each of the three NF-kB inhibitors
but instead exacerbated it. This suggests the
alternative, and more likely, hypothesis that
PDTC, TPCK and calpain I inhibitor are inhibit-
ing the transcription of a gene required for cell
survival. One candidate for the putative survival
gene being repressed by the three inhibitors is
A20, a zinc ￿nger binding protein with an NF-
kB site on the promoter known to protect cells
from undergoing apoptosis.24 Recent data from
Beg and Baltimore, however, show that transfec-
tion of Rel A-de￿cient 3T3 cells with A20 is
unable to prevent TNF-induced apoptosis.24 In
contrast, transfection of WEHI cells with c-myc
and Bcl-xL can attenuate apoptosis induced by
TPCK27 suggesting that Bcl-xL and/or c-myc
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promote cell survival.
In summary, our data from a transformed
murine peritoneal macrophage cell line add to a
recent and rapidly growing body of evidence
linking NF-kB inhibition to induction of apopto-
sis in in￿ammatory and immune cells. Induction
of apoptosis in immune effector cells may be a
therapeutic mechanism of NF-kBinhibitors.
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